CYP2A7 pseudogene transcript affects CYP2A6 expression in human liver by acting as a decoy for MIR-126

Drug Metabolism and Disposition

Volumn 43, Issue 5, 2015, Pages 703-712

  Nakano, Masataka ^a   Fukushima, Yasunari ^a   Yokota, Shin Ichi ^a   Fukami, Tatsuki ^a   Takamiya, Masataka ^b   Aoki, Yasuhiro ^b,c   Yokoi, Tsuyoshi ^a   Nakajima, Miki ^a  

^a KANAZAWA UNIVERSITY   (Japan)

^b IWATE MEDICAL UNIVERSITY   (Japan)

^c NAGOYA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCES   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 2A; CYTOCHROME P450 2A6; CYTOCHROME P450 2A7; MESSENGER RNA; MICRORNA 126; UNCLASSIFIED DRUG; 3' UNTRANSLATED REGION; CYP2A6 PROTEIN, HUMAN; CYP2A7 PROTEIN, HUMAN; MICRORNA; MIRN126 MICRORNA, HUMAN; UNSPECIFIC MONOOXYGENASE;

3' UNTRANSLATED REGION; ARTICLE; CONTROLLED STUDY; DOWN REGULATION; ENZYME ACTIVITY; GENE EXPRESSION; HEK293 CELL LINE; HUMAN; HUMAN CELL; HUMAN TISSUE; LIVER; LIVER CELL; PRIORITY JOURNAL; PSEUDOGENE; RNA STABILITY; CELL LINE; GENETIC POLYMORPHISM; GENETICS; METABOLISM;

NICOTIANA TABACUM;

3' UNTRANSLATED REGIONS; ARYL HYDROCARBON HYDROXYLASES; CELL LINE; CYTOCHROME P-450 CYP2A6; DOWN-REGULATION; HEK293 CELLS; HEPATOCYTES; HUMANS; LIVER; MICRORNAS; POLYMORPHISM, GENETIC; PSEUDOGENES; RNA, MESSENGER;

EID: 84940383747     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.115.063255     Document Type: Article

References (31)

1. Al Koudsi N, Hoffmann EB, Assadzadeh A, and Tyndale RF (2010) Hepatic CYP2A6 levels and nicotine metabolism: impact of genetic, physiological, environmental, and epigenetic factors. Eur J Clin Pharmacol 66:239-251.
2. Bartel DP (2004) MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 116:281-297.
3. Ding S, Lake BG, Friedberg T, and Wolf CR (1995) Expression and alternative splicing of the cytochrome P-450 CYP2A7. Biochem J 306:161-166.
4. Fujieda M, Yamazaki H, Saito T, Kiyotani K, Gyamfi MA, Sakurai M, Dosaka-Akita H, Sawamura Y, Yokota J, and Kunitoh H, et al. (2004) Evaluation of CYP2A6 genetic polymorphisms as determinants of smoking behavior and tobacco-related lung cancer risk in male Japanese smokers. Carcinogenesis 25:2451-2458.
5. Fukami T, Nakajima M, Sakai H, McLeod HL, and Yokoi T (2006) CYP2A7 polymorphic alleles confound the genotyping of CYP2A6∗4A allele. Pharmacogenomics J 6:401-412.
6. Fukami T, Nakajima M, Matsumoto I, Zen Y, Oda M, and Yokoi T (2010) Immunohistochemical analysis of CYP2A13 in various types of human lung cancers. Cancer Sci 101:1024-1028.
7. Friedman RC, Farh KK, Burge CB, and Bartel DP (2009) Most mammalian mRNAs are conserved targets of microRNAs. Genome Res 19:92-105.
8. Higashi E, Fukami T, Itoh M, Kyo S, Inoue M, Yokoi T, and Nakajima M (2007) Human CYP2A6 is induced by estrogen via estrogen receptor. Drug Metab Dispos 35:1935-1941.
9. Hu W and Coller J (2012) What comes first: Translational repression or mRNA degradation? The deepening mystery of microRNA function. Cell Res 22:1322-1324.
10. Itoh M, Nakajima M, Higashi E, Yoshida R, Nagata K, Yamazoe Y, and Yokoi T (2006) Induction of human CYP2A6 is mediated by the pregnane X receptor with peroxisome proliferator-activated receptor-g coactivator 1a. J Pharmacol Exp Ther 319:693-702.
11. Kalscheuer S, Zhang X, Zeng Y, and Upadhyaya P (2008) Differential expression of microRNAs in early-stage neoplastic transformation in the lungs of F344 rats chronically treated with the tobacco carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone. Carcinogenesis 29:2394-2399.
12. Koskela S, Hakkola J, Hukkanen J, Pelkonen O, Sorri M, Saranen A, Anttila S, Fernandez- Salguero P, Gonzalez F, and Raunio H (1999) Expression of CYP2A genes in human liver and extrahepatic tissues. Biochem Pharmacol 57:1407-1413.
13. Mohri T, Nakajima M, Fukami T, Takamiya M, Aoki Y, and Yokoi T (2010) Human CYP2E1 is regulated by miR-378. Biochem Pharmacol 79:1045-1052.
14. Nakajima M (2007) Smoking behavior and related cancers: The role of CYP2A6 polymorphisms. Curr Opin Mol Ther 9:538-544.
15. Nakajima M, Fukami T, Yamanaka H, Higashi E, Sakai H, Yoshida R, Kwon JT, McLeod HL, and Yokoi T (2006a) Comprehensive evaluation of variability in nicotine metabolism and CYP2A6 polymorphic alleles in four ethnic populations. Clin Pharmacol Ther 80:282-297.
16. Nakajima M, Itoh M, Sakai H, Fukami T, Katoh M, Yamazaki H, Kadlubar FF, Imaoka S, Funae Y, and Yokoi T (2006b) CYP2A13 expressed in human bladder metabolically activates 4-aminobiphenyl. Int J Cancer 119:2520-2526.
17. Nakajima M, Kuroiwa Y, and Yokoi T (2002) Interindividual differences in nicotine metabolism and genetic polymorphisms of human CYP2A6. Drug Metab Rev 34:865-877.
18. Nakajima M, Yamamoto T, Nunoya K, Yokoi T, Nagashima K, Inoue K, Funae Y, Shimada N, Kamataki T, and Kuroiwa Y (1996) Role of human cytochrome P4502A6 in C-oxidation of nicotine. Drug Metab Dispos 24:1212-1217.
19. Nakajima M and Yokoi T (2011) MicroRNAs from biology to future pharmacotherapy: regulation of cytochrome P450s and nuclear receptors. Pharmacol Ther 131:330-337.
20. Oda Y, Nakajima M, Mohri T, Takamiya M, Aoki Y, Fukami T, and Yokoi T (2012) Aryl hydrocarbon receptor nuclear translocator in human liver is regulated by miR-24. Toxicol Appl Pharmacol 260:222-231.
21. Onica T, Nichols K, Larin M, Ng L, Maslen A, Dvorak Z, Pascussi JM, Vilarem MJ, Maurel P, and Kirby GM (2008) Dexamethasone-mediated up-regulation of human CYP2A6 involves the glucocorticoid receptor and increased binding of hepatic nuclear factor 4 a to the proximal promoter. Mol Pharmacol 73:451-460.
22. Poliseno L, Salmena L, Zhang J, Carver B, HavemanWJ, and Pandolfi PP (2010) A coding-independent function of gene and pseudogene mRNAs regulates tumour biology. Nature 465:1033-1038.
23. Strasser AA, Malaiyandi V, Hoffmann E, Tyndale RF, and Lerman C (2007) An association of CYP2A6 genotype and smoking topography. Nicotine Tob Res 9:511-518.
24. Tiano HF, Hosokawa M, Chulada PC, Smith PB, Wang RL, Gonzalez FJ, Crespi CL, and Langenbach R (1993) Retroviral mediated expression of human cytochrome P450 2A6 in C3H/10T1/2 cells confers transformability by 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK). Carcinogenesis 14:1421-1427.
25. Tsuchiya Y, Nakajima M, Kyo S, Kanaya T, Inoue M, and Yokoi T (2004) Human CYP1B1 is regulated by estradiol via estrogen receptor. Cancer Res 64:3119-3125.
26. Tsuchiya Y, Nakajima M, Takagi S, Taniya T, and Yokoi T (2006) MicroRNA regulates the expression of human cytochrome P450 1B1. Cancer Res 66:9090-9098.
27. Wang J, Pitarque M, and Ingelman-Sundberg M (2006) 39-UTR polymorphism in the human CYP2A6 gene affects mRNA stability and enzyme expression. Biochem Biophys Res Commun 340:491-497.
28. Yamano S, Tatsuno J, and Gonzalez FJ (1990) The CYP2A3 gene product catalyzes coumarin 7-hydroxylation in human liver microsomes. Biochemistry 29:1322-1329.
29. Yanaihara N, Caplen N, Bowman E, Seike M, Kumamoto K, Yi M, Stephens RM, Okamoto A, Yokota J, and Tanaka T, et al. (2006) Unique microRNA molecular profiles in lung cancer diagnosis and prognosis. Cancer Cell 9:189-198.
30. Yokota S, Higashi E, Fukami T, Yokoi T, and Nakajima M (2011) Human CYP2A6 is regulated by nuclear factor-erythroid 2 related factor 2. Biochem Pharmacol 81:289-294.
31. Zhang SY, Surapureddi S, Coulter S, Ferguson SS, and Goldstein JA (2012) Human CYP2C8 is post-transcriptionally regulated by microRNAs 103 and 107 in human liver. Mol Pharmacol 82:529-540.